Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05381948 · ClinicalTrials.gov registry record · Phase 2
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
A Phase 2 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 161
- Enrollment target
NCT05381948 is a Phase 2 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 161 participants.
The verdict
NCT05381948, a Phase 2 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 161 participants
- Enrollment target
Study Summary
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
Interventions
- DRUG EYP-1901
- DRUG Aflibercept 2mg/0.05mL Inj,Oph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05381948
The ClinicalTrials.gov registry entry for NCT05381948 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EYP-1901 is the first listed.
NCT05381948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05381948 about?
NCT05381948 is a clinical study titled "Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)". This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
What is the current status of trial NCT05381948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2022-06-30. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT05381948?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept 2mg/0.05mL Inj,Oph (DRUG).
Who is sponsoring clinical trial NCT05381948?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.